Despite Potential of RNAi, Companies in the Space Keep Pipelines Focused

Although RNAi can be used to knock down virtually any gene of interest, companies working in the space have taken a decidedly measured approach in building their internal pipelines, maintaining a relatively small number of drug-development programs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories